Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 04 2025
0mins
Should l Buy CGTX?
Source: Benzinga
Stock Performance: Cognition Therapeutics Inc (CGTX) saw a significant stock increase of 20.82% during regular trading hours, followed by an additional 12.10% rise in after-hours trading, reaching $0.45.
Drug Trial Success: The surge in stock price is linked to promising results from its Alzheimer's drug, Zervimesine, which achieved a 95% efficacy rate in its Phase 2 trial and reached a 50% enrollment milestone.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGTX
Wall Street analysts forecast CGTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.759
Low
3.00
Averages
3.00
High
3.00
Current: 0.759
Low
3.00
Averages
3.00
High
3.00
About CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cognition Therapeutics Advances CT1812 to Late-Stage Trials for DLB Psychosis
- Clinical Trial Progress: Cognition Therapeutics is advancing zervimesine (CT1812) into late-stage trials for dementia with Lewy bodies (DLB) psychosis, with an $80 million Phase 2 START trial readout expected in the second half of 2027, indicating significant progress in the treatment of neurodegenerative diseases.
- SHIMMER Trial Results: At the International Lewy Body Dementia Conference, zervimesine demonstrated a favorable impact across various symptom domains in the SHIMMER trial, particularly in neuropsychiatric assessments, highlighting its potential in the DLB psychosis market and possibly driving future demand.
- Commitment to Alzheimer's Disease: The Phase 2 SHINE study for mild-to-moderate Alzheimer's disease showed zervimesine achieving cognitive decline reductions comparable to approved monoclonal antibodies, especially in participants with low p-tau217 levels, indicating its therapeutic potential.
- START Study Funding Assurance: The START study has fully enrolled 545 participants with mild cognitive impairment and early Alzheimer's disease, funded by NIH grants, and is expected to provide critical data for the second half of 2027, further advancing zervimesine's clinical development.
See More
Cognition Therapeutics Reports Better-Than-Expected FY GAAP EPS
- Earnings Highlights: Cognition Therapeutics reported a FY GAAP EPS of -$0.32, beating expectations by $0.07, indicating improvements in financial management and increased market confidence.
- Cash Position: As of December 31, 2025, the company had approximately $37.0 million in cash, cash equivalents, and restricted cash, demonstrating robust liquidity that supports future operations and investments.
- Grant Funding Status: The remaining obligated grant funds from the National Institute of Aging total $35.7 million, providing crucial financial support for the company's R&D and enhancing its competitive position in the biopharmaceutical sector.
- Funding Outlook: Cognition Therapeutics estimates that its current cash reserves are sufficient to fund operations and capital expenditures through the second quarter of 2027, indicating strong financial stability and growth potential over the next two years.
See More
Cognition Therapeutics Advances Zervimesine Clinical Development for DLB Psychosis
- Clinical Development Plan: Cognition Therapeutics plans to meet with the FDA Division of Psychiatry in mid-2026 to align on the registrational plan for zervimesine in treating DLB psychosis, addressing a significant unmet need in this patient population and highlighting its market potential.
- Trial Progress: The company has completed enrollment of 545 patients in the early Alzheimer's disease ‘START’ trial, with topline results expected in 2027, which will provide critical data for advancing zervimesine in Alzheimer's disease and potentially enhance its market acceptance.
- Improved Financial Position: As of December 31, 2025, the company reported approximately $37 million in cash and cash equivalents, a significant increase from 2024, indicating effective cash management that supports operations through the second quarter of 2027.
- Decrease in R&D Expenses: Research and development expenses for 2025 were $37.2 million, down from $41.7 million in 2024, primarily due to the completion of the SHINE and SHIMMER clinical trials, reflecting optimization in resource allocation.
See More
COGNITION THERAPEUTICS INC: FDA PSYCHIATRY DIVISION MEETING ANTICIPATED BY MID-2026
Cognition Therapeutics Meeting: Cognition Therapeutics is scheduled to meet with the FDA's Division of Psychiatry to discuss their developments and findings.
Timeline for Expectations: The meeting is anticipated to take place by mid-2026, indicating a timeline for potential advancements in their therapeutic approaches.
See More
Cognition Therapeutics Reports FY Operating Loss of USD 47.799 Million
- Cognition Therapeutics Financial Update: The company reported an income of $47.799 million from its operations.
- Operational Insights: The financial results indicate a significant revenue generation from the company's therapeutic initiatives.
See More
Cognition Advances Zervimesine Development for DLB Psychosis Treatment
- FDA Meeting Outcome: Following the FDA meeting on January 21, 2026, Cognition Therapeutics has decided to pursue a registrational path for zervimesine to treat dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of patients, potentially improving their quality of life and addressing a significant market gap.
- SHIMMER Study Results: In the SHIMMER study, 130 adults with mild-to-moderate DLB received zervimesine, resulting in an 86% improvement in neuropsychiatric symptoms, indicating the drug's potential to enhance daily functioning and possibly transform the treatment landscape for DLB.
- Clinical Trial Design: The next phase of the study will randomize participants to receive either 100mg of zervimesine or a placebo, focusing on measuring symptoms like hallucinations and delusions, which is expected to provide robust data for FDA discussions and expedite the drug's market entry.
- Market Demand: With no approved medications for DLB psychosis and traditional antipsychotics potentially worsening motor function, the development of zervimesine not only meets a critical need but also presents a significant market opportunity for Cognition.
See More
Cognition Therapeutics Advances CT1812 to Late-Stage Trials for DLB Psychosis
- Clinical Trial Progress: Cognition Therapeutics is advancing zervimesine (CT1812) into late-stage trials for dementia with Lewy bodies (DLB) psychosis, with an $80 million Phase 2 START trial readout expected in the second half of 2027, indicating significant progress in the treatment of neurodegenerative diseases.
- SHIMMER Trial Results: At the International Lewy Body Dementia Conference, zervimesine demonstrated a favorable impact across various symptom domains in the SHIMMER trial, particularly in neuropsychiatric assessments, highlighting its potential in the DLB psychosis market and possibly driving future demand.
- Commitment to Alzheimer's Disease: The Phase 2 SHINE study for mild-to-moderate Alzheimer's disease showed zervimesine achieving cognitive decline reductions comparable to approved monoclonal antibodies, especially in participants with low p-tau217 levels, indicating its therapeutic potential.
- START Study Funding Assurance: The START study has fully enrolled 545 participants with mild cognitive impairment and early Alzheimer's disease, funded by NIH grants, and is expected to provide critical data for the second half of 2027, further advancing zervimesine's clinical development.
See More
Cognition Therapeutics Reports Better-Than-Expected FY GAAP EPS
- Earnings Highlights: Cognition Therapeutics reported a FY GAAP EPS of -$0.32, beating expectations by $0.07, indicating improvements in financial management and increased market confidence.
- Cash Position: As of December 31, 2025, the company had approximately $37.0 million in cash, cash equivalents, and restricted cash, demonstrating robust liquidity that supports future operations and investments.
- Grant Funding Status: The remaining obligated grant funds from the National Institute of Aging total $35.7 million, providing crucial financial support for the company's R&D and enhancing its competitive position in the biopharmaceutical sector.
- Funding Outlook: Cognition Therapeutics estimates that its current cash reserves are sufficient to fund operations and capital expenditures through the second quarter of 2027, indicating strong financial stability and growth potential over the next two years.
See More
Cognition Therapeutics Advances Zervimesine Clinical Development for DLB Psychosis
- Clinical Development Plan: Cognition Therapeutics plans to meet with the FDA Division of Psychiatry in mid-2026 to align on the registrational plan for zervimesine in treating DLB psychosis, addressing a significant unmet need in this patient population and highlighting its market potential.
- Trial Progress: The company has completed enrollment of 545 patients in the early Alzheimer's disease ‘START’ trial, with topline results expected in 2027, which will provide critical data for advancing zervimesine in Alzheimer's disease and potentially enhance its market acceptance.
- Improved Financial Position: As of December 31, 2025, the company reported approximately $37 million in cash and cash equivalents, a significant increase from 2024, indicating effective cash management that supports operations through the second quarter of 2027.
- Decrease in R&D Expenses: Research and development expenses for 2025 were $37.2 million, down from $41.7 million in 2024, primarily due to the completion of the SHINE and SHIMMER clinical trials, reflecting optimization in resource allocation.
See More
COGNITION THERAPEUTICS INC: FDA PSYCHIATRY DIVISION MEETING ANTICIPATED BY MID-2026
Cognition Therapeutics Meeting: Cognition Therapeutics is scheduled to meet with the FDA's Division of Psychiatry to discuss their developments and findings.
Timeline for Expectations: The meeting is anticipated to take place by mid-2026, indicating a timeline for potential advancements in their therapeutic approaches.
See More
Cognition Therapeutics Reports FY Operating Loss of USD 47.799 Million
- Cognition Therapeutics Financial Update: The company reported an income of $47.799 million from its operations.
- Operational Insights: The financial results indicate a significant revenue generation from the company's therapeutic initiatives.
See More
Cognition Advances Zervimesine Development for DLB Psychosis Treatment
- FDA Meeting Outcome: Following the FDA meeting on January 21, 2026, Cognition Therapeutics has decided to pursue a registrational path for zervimesine to treat dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of patients, potentially improving their quality of life and addressing a significant market gap.
- SHIMMER Study Results: In the SHIMMER study, 130 adults with mild-to-moderate DLB received zervimesine, resulting in an 86% improvement in neuropsychiatric symptoms, indicating the drug's potential to enhance daily functioning and possibly transform the treatment landscape for DLB.
- Clinical Trial Design: The next phase of the study will randomize participants to receive either 100mg of zervimesine or a placebo, focusing on measuring symptoms like hallucinations and delusions, which is expected to provide robust data for FDA discussions and expedite the drug's market entry.
- Market Demand: With no approved medications for DLB psychosis and traditional antipsychotics potentially worsening motor function, the development of zervimesine not only meets a critical need but also presents a significant market opportunity for Cognition.
See More
